Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

TAS-102

  • You have access
    Efficacy of a Novel Oral Chemotherapeutic Agent, TAS-102, Against Human Oral Squamous Cell Carcinoma Cells
    KOJI HARADA, TARANNUM FERDOUS and KATSUAKI MISHIMA
    Anticancer Research December 2021, 41 (12) 6039-6049; DOI: https://doi.org/10.21873/anticanres.15423
  • You have access
    The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab
    HIDEKAZU KURAMOCHI, TAKESHI YAMADA, YOICHIRO YOSHIDA, AKIHISA MATSUDA, HIROHIKO KAMIYAMA, CHIHIRO KOSUGI, KEIICHIRO ISHIBASHI, ATSUKO FUKAZAWA, KEISUKE IHARA, HIROMICHI SONODA, KAZUHIKO YOSHIMATSU, HIROSHI YOSHIDA, SUGURU HASEGAWA, KAZUHIRO SAKAMOTO, HIDEYUKI ISHIDA, KEIJI KODA and On behalf of the TAS CC3 Study Group
    Anticancer Research June 2021, 41 (6) 3131-3137; DOI: https://doi.org/10.21873/anticanres.15098
  • You have access
    Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
    TETSUO ISHIZAKI, JUNICHI MAZAKI, MASANOBU ENOMOTO, MASATOSHI SHIGOKA, KENTA KASAHARA, TAKAAKI MATSUDO, HIDEAKI KAWAKITA, YUICHI NAGAKAWA, KENJI KATSUMATA and AKIHIKO TSUCHIDA
    Anticancer Research April 2021, 41 (4) 2157-2163; DOI: https://doi.org/10.21873/anticanres.14988
  • You have access
    Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment
    YUSUKE NIISATO, TOSHIKAZU MORIWAKI, SHOTA FUKUOKA, TOSHIKI MASUISHI, ATSUO TAKASHIMA, YOSUKE KUMEKAWA, TAKESHI KAJIWARA, KENTARO YAMAZAKI, TAITO ESAKI, AKITAKA MAKIYAMA, TADAMICHI DENDA, YUKIMASA HATACHI, TAKESHI SUTO, NAOTOSHI SUGIMOTO and YASUHIRO SHIMADA
    Anticancer Research April 2021, 41 (4) 2203-2207; DOI: https://doi.org/10.21873/anticanres.14996
  • You have access
    Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer
    MASATSUNE SHIBUTANI, HISASHI NAGAHARA, TATSUNARI FUKUOKA, YASUHITO ISEKI, EN WANG, YUKI OKAZAKI, SHINICHIRO KASHIWAGI, KIYOSHI MAEDA, KOSEI HIRAKAWA and MASAICHI OHIRA
    Anticancer Research July 2020, 40 (7) 4157-4163; DOI: https://doi.org/10.21873/anticanres.14415
  • You have access
    Pretreatment Neutrophil–to–Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer
    AKIHISA MATSUDA, TAKESHI YAMADA, SATOSHI MATSUMOTO, NOBUYUKI SAKURAZAWA, YOUICHI KAWANO, ERIKO SHINOZUKA, KUMIKO SEKIGUCHI, HIDEYUKI SUZUKI and HIROSHI YOSHIDA
    Anticancer Research August 2019, 39 (8) 4343-4350; DOI: https://doi.org/10.21873/anticanres.13602
  • You have access
    Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer
    MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA
    Anticancer Research February 2019, 39 (2) 1029-1034; DOI: https://doi.org/10.21873/anticanres.13209
  • You have access
    Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer
    YOICHIRO YOSHIDA, RYOHEI SAKAMOTO, RYUJI KAJITANI, TARO MUNECHIKA, YOSHIKO MATSUMOTO, AKIRA KOMONO, NAOYA AISU, KOJIMA DAIBO, FUMIHIKO KIYOMI and SUGURU HASEGAWA
    Anticancer Research July 2018, 38 (7) 4367-4373; DOI: https://doi.org/10.21873/anticanres.12738
  • You have access
    Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    HIDEJIRO KAWAHARA, TAKASHI MOURI, KOTA ISHIDA, NORI MATSUMOTO, TADASHI AKIBA and KATSUHIKO YANAGA
    Anticancer Research April 2018, 38 (4) 2419-2422;
  • You have access
    Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
    TOSHINORI SUEDA, DAISUKE SAKAI, TOSHIHIRO KUDO, TAKASHI SUGIURA, HIDEKAZU TAKAHASHI, NAOTSUGU HARAGUCHI, JUNICHI NISHIMURA, TAISHI HATA, TARO HAYASHI, TSUNEKAZU MIZUSHIMA, YUICHIRO DOKI, MASAKI MORI and TAROH SATOH
    Anticancer Research August 2016, 36 (8) 4299-4306;

Pages

  • Next
  • 1
  • 2
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire